Lakewood-Amedex Biotherapeutics Inc. (LABT) earnings
Quarterly results of Lakewood-Amedex Biotherapeutics Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 4 quarters, the latest results release and when the next one is expected.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Lakewood-Amedex Biotherapeutics Inc. reported revenue of - and a net loss of $3.8M.
Diluted earnings per share were -$2.75.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | - | - | -$3.8M | -$2.75 |
| Q1 FY2026 | - | - | -$923.3K | -$0.20 |
| Q2 FY2026 | - | - | -$655.9K | -$1.66 |
| Q1 FY2026 | - | - | -$539.6K | -$0.15 |
Results filings
- Quarterly report 10-Q
- Quarterly report 10-Q
Get an email when LABT reports
Follow LABT and we email you its next results the day they are filed, with the numbers explained.